PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026BJC Reports1 citationsOpen Access

Changes in levels of endocannabinoidome mediators in mice with cancer cachexia: links with steatosis and gut microbial dysbiosis

ADAlexandra L. DegraeveACAdele CutignanoFPFabiana Piscitelli

Key Points

  • To investigate changes in endocannabinoidome mediators and gut microbiome in mice with cancer cachexia.
  • Mice injected with colon carcinoma 26 cells were used as a model for cancer cachexia.
  • Mass spectrometry-based targeted lipidomics measured eCBome mediator levels in liver and intestine.
  • Gut microbial composition was analyzed using PERMANOVA to assess dysbiosis.
  • 10 days post-injection, mice exhibited more than 10% weight loss and significant alterations in eCBome lipid levels.
  • Liver showed a decrease in 2-AG (-30%) while jejunal levels of 2-AG increased (+30%).
  • Gut dysbiosis was confirmed with significant changes in microbial phyla, particularly a 1484% increase in Proteobacteria.

Abstract

Cachexia is a debilitating syndrome associated with involuntary weight loss, often occurring in cancer patients. In both humans and animal models, alterations in endocannabinoid (eCB) signaling occur in association with both metabolic disorders and several types of tumors. The wider signaling system, including the two eCBs, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), their congeners and other long chain fatty acid amides, as well as their metabolic enzymes and receptors, is known as endocannabinoidome (eCBome). The eCBome is involved, among others, in the control of energy balance and cancer and interacts with the gut microbiome. Using mass spectrometry-based targeted lipidomics, we measured the hepatic and intestinal concentrations of eCBome mediators in mice injected with colon carcinoma 26 (C26) cells, a model of cancer cachexia characterized, among others, by weight loss, hepatic dyslipidemia, and gut microbiome dysbiosis. We report that, 10 days after C26 cell injection, concomitant with >10% weight loss, eCBome lipids levels, namely 2-AG, AEA, and some of its N-acyl-ethanolamine congeners, as well as N-oleoyl-glycine, N-acyl-serotonins, and N-acyl-taurines (NATs), are altered in intestinal sections and the liver of C26 mice (e.g., hepatic 2-AG -30%, jejunal 2-AG + 30%, jejunal AEA -55%, hepatic N-oleoyl-ethanolamine (OEA) + 223%, hepatic NATs +144%, +141%, +216%). Gut dysbiosis was evident in these mice (PERMANOVA at the family level: R² = 69%, p < 0.001), with altered levels in 3 phyla (mainly the Proteobacteria, +1484%), 12 families, and 12 genera (all with adjusted p < 0.05). Additionally, 2-AG, AEA, OEA, N-arachidonoyl-serotonin, and NAT levels in the liver positively correlated with hepatic total lipids, triglycerides, and cholesterol, whereas N-docosahexaenoyl-ethanolamine and N-docosahexaenoyl-serotonin showed negative correlations. Jejunal AEA negatively, and hepatic OEA and NATs positively, correlated with weight loss. Intestinal eCBome mediators correlated with several cecal microbial taxa, including genera known to include strains beneficial in metabolic disorders, such as Bacteroides, Parabacteroides, Dysosmobacter, and Prevotella. These observations pinpoint eCBome mediators as new multi-functional players in the hepatic complications and gut dysbiosis accompanying cancer cachexia.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Degraeve et al. (2026) studied this question.

synapsesocial.com/papers/69aa70b8531e4c4a9ff5ab8bhttps://doi.org/10.1038/s44276-026-00208-y
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity2005 · 926 citations
  2. 2NewN-Arachidonoylserotonin Analogues with Potential “Dual” Mechanism of Action against Pain2007 · 66 citations
  3. 3Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia2015 · 212 citations
  4. 4Cancer cachexia: involvement of an expanding macroenvironment2023 · 41 citations
  5. 5Hepatic alterations during the development and progression of cancer cachexia2019 · 59 citations